Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
- Conditions
- Interventions
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2016-05-09
- Target Recruit Count
- 21
- Registration Number
- NCT01212380
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT01204164
- Locations
- 🇺🇸
MDACC, Houston, Texas, United States
🇺🇸RMCC, Denver, Colorado, United States
🇺🇸Cornell, New York City, New York, United States
Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT01137747
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-03-04
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 792
- Registration Number
- NCT01080391
- Locations
- 🇺🇸
Providence St. Joseph Medical Center, Burbank, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 64
- Registration Number
- NCT01057225
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
UARK 2009-32 Compassionate Use Study of Carfilzomib
- Conditions
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT00999414
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 101
- Registration Number
- NCT00884312
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT00721734
- Locations
- 🇺🇸
University of California- San Francisco, San Francisco, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 84
- Registration Number
- NCT00603447
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 164
- Registration Number
- NCT00530816
- Locations
- 🇺🇸
Therapeutic Research Institute of Orange County, Laguna Hills, California, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.